Meta-analysis of chemotherapy combined with cytokine-induced killer cells in the treatment of ovarian cancer
DUAN Wenli1 WANG Feng2 ZHANG Yan1 ZHOU Hang1
1.Department of Abdominal Oncology, Affiliated Hospital of Zunyi Medical University, Guizhou Province, Zunyi 563000,China;
2.School of Public Health, Zunyi Medical University, Guizhou Province, Zunyi 563000, China
Abstract：Objective To evaluate the effectiveness of chemotherapy combined with cytokine-Induced killer cells (CIK) in the treatment of ovarian cancer. Methods "Cytokine-induced killer cells" "CIK" "DC-CIK" "chemotherapy" "ovarian cance" as the retrieval words, the databases such as PubMed, Embase, the Cochrane Library, Medline, CNKI, VIP and WanFang Date were retrieved from the time of the database established to June 2017. Satisfactory randomized controlled clinical trial (RCT) or non-randomized concurrent control trial (NRCCT) were included. Meta-analysis was conducted by RevMan 5.3 software. Results Overall, 10 studies involving 788 patients with ovarian cancer were included. The results of Meta-analysis showed that, compared with chemotherapy alone group, the response rate (OR=1.93, 95%CI: 1.36-2.74, P=0.0002), disease control rate (OR=2.42, 95%CI: 1.46-4.02, P=0.0007), 1-year survival rate (OR=2.71, 95%CI:1.46-5.03, P=0.002), 2-year survival rate (OR=2.30, 95%CI: 1.31-4.04, P=0.004) and progression-free survival (MD=3.66, 95%CI: 1.31-6.01, P=0.002) in the chemotherapy combined with adoptive transfer of CIK group were improved. However, there were no significant differences between two groups in overall survival (MD=4.75, 95%CI: -3.58 -13.07, P=0.26). Conclusion For patients with ovarian cancer, the adoptive transfer of CIK can improve the efficacy of chemotherapy and delay progression, but it has no significant effect on the overall survival.
2017, Vol. 14 
京公网安备 11010502046598号